The IASLC's 2023 Molecular Testing for Targeted Therapies in Lung Cancer Atlas is now available
The IASLC’s latest Atlas provides a comprehensive overview of all current and emerging molecular targets, specimen acquisition, available assays, and reporting and interpretation of molecular testing results from both a diagnostic and clinical perspective.
Download the PDF Version
Background
The IASLC has produced several atlases dealing with a range of lung cancer biomarker testing topics, including ALK, ROS1, EGFR, and PD-L1, and an Atlas on immunohistochemistry for lung cancer diagnosis. These atlases have been extremely popular and have provided state-of-the-art, concisely presented information on clinical, pathological, and molecular testing aspects of the subject material in a user-friendly package.
Purpose
The IASLC intends to produce a comprehensive atlas covering all current and emerging targets from both a diagnostic and clinical point of view. There will be dedicated chapters for each ‘marker’ – EGFR, ALK, ROS1, MET, KRAS, RET, NTRK, NRG, and HER2 each written by pathologists and oncologists, covering both the therapeutic and the testing aspects relevant to each family of genomic alterations. The atlas will also cover a few broadly focused chapters covering various aspects of precision medicine in lung cancer, like specimen acquisition and handling of tumor samples, the different available assays, and interpretation of results to reporting and quality assurance. This atlas aims to serve as a comprehensive, concise, and hands-on educational resource for multidisciplinary medical professionals.
Educational Objectives
- Provide pathologists with “know-how” educational information on specimen acquisition (tissue and liquid), pre-analytical conditions, and molecular testing.
- Provide oncologists with the “know-why” educational information on how to interpret and potentially apply the results for a therapy where medically appropriate.
- Serve as an educational tool and hands-on resource for multidisciplinary medical professionals involved in precision medicine worldwide.
Editors
Lynette Sholl
MD
Associate Professor of Pathology and Associate Pathologist
Harvard Medical School
Brigham and Women's Hospital
Wendy A. Cooper
PhD, MB, BS, BSc(Med), FRCPA
Associate Professor, Department of Pathology
Royal Prince Alfred Hospital
Keith Kerr
MD, FRCPath
Professor of Pulmonary Pathology
University of Aberdeen, School of Medicine and Dentistry
Daniel S.W. Tan
MD
Senior Consultant, Medical Oncology
National Cancer Centre Singapore
Ming Sound Tsao
MD
Pathologist, Senior Scientist, and Professor Department of Pathology
Princess Margaret Cancer Centre, University of Toronto Health Network
- Foreword from IASLC
- Introduction
- Clinical relevance of biomarker testing in lung cancer, including perspectives for community oncologists and patient advocates
- Specimen acquisition and pre-analytical considerations
- Tissue-based
- Pulmonary perspective
- Surgical perspective
- Interventional radiologist perspective
- Pathology –tissue sample (surgical, core needle) and cytology
- Tissue-based
- Liquid biopsy – Specimen acquisition, testing strategies, and clinical roles
- Specimen handling and processing, testing strategies
- Clinical roles
- Technologies for the detection of biomarkers
- A global perspective on molecular testing with a focus on guidelines
- EGFR
- ALK
- ROS1
- BRAF
- NTRK
- RET
- MET
- KRAS
- HER2
- NRG
Each chapter features a pathologist and medical oncologist as they explore the individual gene/target including:
- New targets and technologies
- Reporting and interpretation of biomarker testing results and role of multidisciplinary tumor board post results
- Molecular testing algorithm
- Summary and future perspectives
